Table 3. Treatment-related AEs (N=242).
| AEs | n (%) | ||
| Any grade | Grade 1−2 | Grade 3−4 | |
| AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase. | |||
| Fatigue | 136 (56.2) | 131 (54.1) | 5 (2.1) |
| Hypertension | 88 (36.4) | 82 (33.9) | 6 (2.5) |
| Hypothyroidism | 79 (32.6) | 79 (32.6) | 0 (0) |
| Hand-foot syndrome | 68 (28.1) | 68 (28.1) | 0 (0) |
| Lymphocytopenia | 56 (23.1) | 56 (23.1) | 0 (0) |
| Anemia | 41 (16.9) | 41 (16.9) | 0 (0) |
| Proteinuria | 37 (15.3) | 33 (13.6) | 4 (1.7) |
| Hoarseness | 36 (14.9) | 36 (14.9) | 0 (0) |
| ALT elevation | 32 (13.2) | 31 (12.8) | 1 (0.4) |
| AST elevation | 27 (11.2) | 26 (10.7) | 1 (0.4) |
| Neutropenia | 26 (10.7) | 26 (10.7) | 0 (0) |
| Rash | 26 (10.7) | 26 (10.7) | 0 (0) |
| Hemoptysis | 18 (7.4) | 17 (7.0) | 1 (0.4) |
| Immune pneumonitis | 14 (5.8) | 11 (4.5) | 3 (1.2) |
| Thrombocytopenia | 15 (6.2) | 15 (6.2) | 0 (0) |
| Immune myocarditis | 6 (2.5) | 5 (2.1) | 1 (0.4) |